Megestrol Acetate

Megestrol acetate is a synthetic derivative of progesterone belonging to the progestin class of drugs. First synthesized in the late 1950s, it was initially used in the 1960s as a component of combined oral contraceptives, but that use was largely abandoned after animal toxicity concerns. It was later developed for oncology, gaining approval for endometrial cancer, and in 1993 it was approved in the United States for the treatment of anorexia, cachexia, or unexplained weight loss in patients with AIDS ^[1][2]. It is widely known by the brand name Megace and is available generically, including as tablets and a concentrated oral suspension.

The best-established modern use of megestrol acetate is as an appetite stimulant in wasting conditions. In cancer-related anorexia-cachexia, controlled trials and their pooled analyses show that it increases appetite and produces modest weight gain compared with placebo, with a meta-analysis estimating that only a few patients need to be treated for one to gain appetite and somewhat more for one to gain weight ^[3]. However, the additional weight is not consistently accompanied by improved quality of life, and the drug does not prolong survival ^[1][3]. Comparisons suggest its effect on appetite and weight is broadly similar to that of corticosteroids ^[3].

In oncology, megestrol acetate is used as a hormonal agent, historically as a second-line treatment for hormone-responsive breast cancer and for endometrial cancer, where its progestogenic and antigonadotropic actions oppose hormone-driven tumor growth ^[1]. It has also been studied in other settings of weight loss, including in older adults, though the evidence there is weaker ^[1]. Across indications, updated systematic reviews emphasize that benefits are limited mainly to appetite and weight, and that patients should be counseled about the associated risks ^[1][2].

Megestrol acetate is a prescription medicine available worldwide, including as generics ^[1]. Reported adverse effects include fluid retention and edema, an increased tendency to form blood clots, elevated blood sugar and adrenal-suppressing, glucocorticoid-like effects at higher doses, and, because it suppresses sex hormone production, reduced libido and hypogonadism ^[2]. Systematic reviews note that edema, thromboembolic events, and deaths were more frequent among treated patients in the pooled trials, which is why its use in frail, palliative populations calls for careful weighing of benefits and harms ^[2].

Megestrol is prescription only. The intended weight gain comes with fluid retention and can raise blood pressure and blood sugar, sometimes unmasking diabetes. Because it has steroid-like activity, it can suppress the adrenal axis, so stopping it after long use may cause adrenal insufficiency. A more serious risk is blood clots in the legs or lungs, and it can cause breakthrough vaginal bleeding and mood changes. It should not be used in pregnancy. It can interact with warfarin and with the arrhythmia drug dofetilide, which should be avoided.

Megestrol acetate exhibits glucocorticoid properties that significantly impair glucose homeostasis and interact with antidiabetic medications. Patients receiving megestrol frequently develop severe hyperglycemia due to its insulin-antagonistic effects, requiring intensification of glucose-lowering therapy; one documented case involved a patient whose blood glucose remained poorly controlled despite escalating basal insulin until megestrol and competing glucose-affecting medications were discontinued, after which glycemic control rapidly improved ^[4].

The hyperglycemic effect is direct and not mediated by changes in drug metabolism, making it a pharmacodynamic rather than pharmacokinetic interaction. Patients with diabetes or glucose intolerance should have blood glucose monitored closely during megestrol therapy, and antidiabetic regimens may need adjustment upward to account for megestrol's metabolic effects.

Checking a whole stack? Run it through interactions + stacks.

Megestrol acetate is a synthetic progestin first prepared in the early 1960s, part of the wave of steroidal progestins developed in that era for hormonal and contraceptive use. Its clinical applications broadened over the following decades; it was employed as a hormonal treatment for advanced breast and endometrial cancers, taking advantage of its antigonadotropic action, before its striking effect on appetite and weight came to the fore.

A pivotal milestone arrived in 1993, when the United States Food and Drug Administration approved megestrol acetate for the treatment of anorexia, cachexia, or unexplained weight loss in patients with acquired immunodeficiency syndrome, and its use in cancer-related wasting followed. A concentrated oral suspension, marketed as Megace ES, was later introduced to improve dosing. Notably, the precise mechanism by which the drug stimulates appetite has never been fully explained, though actions on hypothalamic neuropeptide Y and on inflammatory cytokines are thought to contribute.

Megestrol acetate has a well-earned reputation as one of the most dependable appetite stimulants available, and for people facing the distressing weight loss of the anorexia-cachexia syndrome it can offer meaningful help. Systematic reviews, including an updated Cochrane analysis of dozens of trials, consistently find that it improves appetite and produces modest weight gain in patients with cancer, AIDS, and other wasting conditions, an effect that has made it a longstanding palliative tool.

Its value is genuine but should be understood honestly; the same reviews report that the weight gained does not clearly translate into better quality of life or longer survival, and that the drug carries risks including fluid retention, blood clots, and suppression of the body's own cortisol production. Used thoughtfully, with informed discussion of these tradeoffs, it remains a useful option when restoring appetite is a priority.